

## New Hampshire Medicaid Fee-for-Service Program

### Horizant® Criteria

Approval Date: July 12, 2022

#### Medication

Brand Name	Generic Name	Dosage Strength(s)
Horizant®	gabapentin enacarbil	300 mg, 600 mg

#### Criteria for Approval

1. Diagnosis of restless legs syndrome (RLS); **AND**
  - a. Trial and failure of gabapentin IR; **AND**
  - b. Trial and failure or contraindication to of **ONE** of the following:
    - i. Levodopa/carbidopa **OR**
    - ii. Pramipexole; **OR**
    - iii. Ropinirole; **OR**
2. Diagnosis of postherpetic neuralgia (PHN); **AND**
  - a. Failure of, or non-candidacy for, any tricyclic antidepressant or generic gabapentin IR treatment; **AND**
  - b. Failure of, or non-candidacy for generic pregabalin.

#### Criteria for Denial

Criteria for approval not met

**Length of Approval:** One year

#### References

Available upon request.

#### Revision History

Reviewed by	Reason for Review	Date
DUR Board	New	10/19/2011

Proprietary & Confidential

© 2011–2022 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

Reviewed by	Reason for Review	Date
Commissioner	Approval	04/12/2012
DUR Board	Update	09/27/2018
Commissioner Designee	Approval	11/27/2018
DUR Board	Update	10/28/2019
Commissioner Designee	Approval	12/03/2019
DUR Board	Update	12/15/2020
Commissioner Designee	Approval	02/24/2021
DUR Board	Revision	06/02/2022
Commissioner Designee	Approval	07/12/2022